During the past decade, CH de Cannes conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 2 clinical trials were completed, i.e. on average, 6.7% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 2 clinical trials were completed. i.e. 12.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH de Cannes" #1 sponsor was "Centre Hospitalier Universitaire de Nice" with 9 trials, followed by "Intergroupe Francophone de Cancerologie Thoracique" with 8 trials sponsored, "The Lymphoma Academic Research Organisation" with 6 trials sponsored, "Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche" with 2 trials sponsored and "GERCOR - Multidisciplinary Oncology Cooperative Group" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH de Cannes" #1 collaborator was "Hoffmann-La Roche" with 2 trials as a collaborator, "Bio-Rad Laboratories" with 1 trials as a collaborator, "Biotronik SE & Co. KG" with 1 trials as a collaborator, "Bordeaux PharmacoEpi" with 1 trials as a collaborator and "CHU de Nancy" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "CH de Cannes" are "Rheumatoid Arthritis" (3 trials), "Acute Coronary Syndrome" (2 trials), "COVID" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "CH de Cannes" in a lesser frequency.

Most popular intervention types in "CH de Cannes" are "Drug" (17 trials), "Other" (14 trials), "Device" (8 trials), "Procedure" (4 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pemetrexed" (3 trials), "Gemcitabine" (2 trials), "Lenalidomide" (2 trials), "Rituximab" (2 trials) and "additional blood tubes" (2 trials). Other intervention names were less common.

The vast majority of trials in "CH de Cannes" are 50 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CH de Cannes". undefined are not yet recruiting, 14 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in CH de Cannes, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in CH de Cannes, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 17 trials that are defined as “Not Applicable".